Bingcheng Liu Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

1/2021	A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
10/2020	Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function.
5/2020	Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report.
1/2020	Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
3/2019	Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up.
4/2018	Prognostic significance of copy number alterations detected by multi-link probe amplification of multiple genes in adult acute lymphoblastic leukemia.
10/2014	[Optimal treatment of adult Ph negative acute lymphoblastic leukemia].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bingcheng Liu Research Topics

Disease

13	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2024 - 09/2002
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 10/2011
7	Leukemia 09/2021 - 11/2014
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 10/2014
6	Alopecia (Baldness) 04/2024 - 01/2020
6	Philadelphia Chromosome 01/2021 - 11/2014
2	Neutropenia 01/2021 - 01/2017
2	Blast Crisis (Blast Phase) 01/2021 - 09/2002
2	Cytokine Release Syndrome 10/2020 - 05/2020
1	Cicatrix (Scar) 10/2022
1	Folliculitis (Sycosis) 03/2021
1	Reperfusion Injury 03/2021
1	Pruritus (Itching) 03/2021
1	Anemia 01/2021
1	Hypophosphatemia 01/2021
1	Diarrhea 01/2021
1	Edema (Dropsy) 01/2021
1	Exanthema (Rash) 01/2021
1	Pain (Aches) 01/2021
1	AIDS-Related Complex (ARC) 08/2020
1	Lymphoma (Lymphomas) 05/2020
1	Brain Diseases (Brain Disorder) 05/2020
1	Skin Neoplasms (Skin Cancer) 05/2020
1	Candidemia 01/2020
1	Wounds and Injuries (Trauma) 01/2018
1	Tissue Adhesions 01/2018
1	Infections 01/2017
1	Acute Promyelocytic Leukemia 03/2015
1	Mycoses (Diseases, Fungus) 01/2015
1	Chromosome Aberrations (Chromosome Abnormalities) 12/2014
1	Pulmonary Arterial Hypertension 07/2014
1	Dyspnea (Shortness of Breath) 07/2014

Drug/Important Bio-Agent (IBA)

6	Imatinib Mesylate (Gleevec)FDA Link 02/2024 - 07/2014
4	Dasatinib (BMS 354825)FDA Link 02/2024 - 07/2014
4	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2022
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 12/2014
3	olverembatinibIBA 01/2023 - 01/2022
3	Chimeric Antigen ReceptorsIBA 10/2020 - 01/2020
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 04/2024 - 03/2015
2	nilotinib FDA Link 02/2024 - 03/2019
2	flumatinibIBA 02/2024 - 01/2021
2	venetoclaxIBA 01/2022 - 09/2021
1	CateninsIBA 04/2024
1	Androgen Receptors (Androgen Receptor)IBA 01/2023
1	Dihydrotestosterone (Androstanolone)IBA 01/2023
1	COVID-19 VaccinesIBA 01/2022
1	Azacitidine (5 Azacytidine)FDA Link 09/2021
1	alanyl-leucyl-alanyl-leucine (ALAL)IBA 09/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	ruxolitinibIBA 10/2020
1	Janus KinasesIBA 10/2020
1	CytokinesIBA 10/2020
1	SteroidsIBA 10/2020
1	HydrogelsIBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	Antifungal AgentsIBA 01/2020
1	CBFbeta-MYH11 fusion proteinIBA 10/2018
1	Core Binding Factors (Core-Binding Factor)IBA 10/2018
1	Cyclin-Dependent Kinase Inhibitor p16IBA 04/2018
1	Cytokine Receptors (Cytokine Receptor)IBA 04/2018
1	Co-Repressor ProteinsIBA 04/2018
1	GelsIBA 01/2018
1	HLA-DR Antigens (HLA-DR)IBA 01/2017
1	Mitoxantrone (Novantrone)FDA LinkGeneric 02/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2016
1	HomoharringtonineIBA 03/2015
1	Caspofungin (Cancidas)FDA Link 01/2015
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2011
1	indirubinIBA 09/2002
1	Hydroxyurea (Hydrea)FDA LinkGeneric 09/2002
1	N-methylisoindigotinIBA 09/2002
1	Busulfan (Busulfex)FDA Link 09/2002

Therapy/Procedure

12	Therapeutics 02/2024 - 11/2014
6	Drug Therapy (Chemotherapy) 09/2021 - 10/2014
3	Transplantation 10/2022 - 08/2020
2	Consolidation Chemotherapy 01/2017 - 03/2015
1	Drug Tapering 01/2023
1	Hyperbaric Oxygenation 03/2021
1	Surgical Instruments (Clip) 08/2020
1	Cell- and Tissue-Based Therapy (Cell Therapy) 05/2020
1	Ligation 04/2018
1	Sutures (Suture) 01/2018
1	Induction Chemotherapy 01/2017
1	Hematopoietic Stem Cell Transplantation 12/2014